AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30500960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterotomy extension
Number of subjects: 1038
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in eGFR in the 1st year
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in eGFR over 36 months
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR ≥1 KDOQI class of CKD after 3 years
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st 12 months
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eGFR associated with outcomes
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR over the 1st year
Number of subjects: 6934
Study 27638233 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st year
Number of subjects: 6934
Study 25794285 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10.0 ± 4.0 mg/day)
Number of subjects: 41
Study 25794285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (78.6 ± 26.7 mg/day)
Number of subjects: 41
Study 25794285 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release formulation (18.8 ± 8.8 mg/day)
Number of subjects: 41
Study 23453932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz)
Number of subjects: 8
Study 23453932 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS (sham)
Number of subjects: 8
Study 21856692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 week physiotherapy led group delivered strength and balance training programme with supplementary home exercises
Number of subjects: 130
Study 21856692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 19557566 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared (IR) treatment for 20 minutes
Number of subjects: 21
Study 19557566 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) treatment for 10 minutes
Number of subjects: 21
Study 17284134 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight score (measured by Birchwood Insight Scale)
Number of subjects: 0
Study 16129844 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF schedule 5 (300 microg/d days 8 and 12)
Number of subjects: 506
Study 16129844 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (any schedule)
Number of subjects: 506
Study 11166906 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 vaccine
Number of subjects: 72
Study 11166906 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 and SF-2 rgp120 subunit vaccines
Number of subjects: 72
Study 9499214 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 99
Study 9499214 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 99
Study 7899036 — intervention group
Group type: EXPERIMENTAL
Intervention: RDKs with varying frame durations
Number of subjects: 0
Study 7899036 — intervention group
Group type: COMPARATOR
Intervention: RDKs with varying displacement sizes
Number of subjects: 0
Study 7899036 — intervention group
Group type: EXPERIMENTAL
Intervention: RDKs with varying speeds
Number of subjects: 0
Study 3300128 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 0
Study 3300128 — intervention group
Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 0
Study 3300128 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 3300128 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII and MI
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift workers
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers or former smokers
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumers or former consumers of alcoholic beverages
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Employees with higher education
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents in the company's headquarter city
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with better Brazilian economic classification
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 0
Study 30892498 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 0
Study 28153755 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 28153755 — intervention group
Group type: COMPARATOR
Intervention: Non-buffered 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 25372774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU vitamin D3 pearl, 2 times during the study: at baseline and day 21)
Number of subjects: 45
Study 25372774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 placebos at baseline and day 21)
Number of subjects: 45
Study 25372774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 45
Study 25372774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23759804 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification system guided postural intervention (CSPI)
Number of subjects: 49
Study 23759804 — intervention group
Group type: COMPARATOR
Intervention: Generalized postural intervention (GPI)
Number of subjects: 49
Study 23759804 — intervention group
Group type: EXPERIMENTAL
Intervention: CSPI
Number of subjects: 49
Study 23759804 — intervention group
Group type: COMPARATOR
Intervention: GPI
Number of subjects: 49
Study 21158953 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of ascorbic acid (AA)/kg diet
Number of subjects: 420
Study 21158953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing metabolizable energy (ME) level by oil supplementation
Number of subjects: 420
Study 21158953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing ME with or without essential amino acids (EAA)
Number of subjects: 420
Study 21158953 — intervention group
Group type: COMPARATOR
Intervention: Positive control (thermo-neutral conditions with corn-soybean meal diet)
Number of subjects: 420
Study 21158953 — intervention group
Group type: COMPARATOR
Intervention: Negative control (corn-soybean meal diet without supplementation)
Number of subjects: 420
Study 21158953 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Met, Lys and Arg concentration
Number of subjects: 420
Study 18200351 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers recruited for a smoking cessation clinical trial
Number of subjects: 0
Study 18200351 — intervention group
Group type: COMPARATOR
Intervention: General smoking population in Rio de Janeiro
Number of subjects: 0
Study 16643264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (immediate feedback about self-reported psychosocial well-being)
Number of subjects: 80
Study 16643264 — intervention group
Group type: COMPARATOR
Intervention: Control (no immediate feedback)
Number of subjects: 80
Study 12805552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential presentation of the stimulus at one location
Number of subjects: 0
Study 12805552 — intervention group
Group type: COMPARATOR
Intervention: Random presentation of the stimulus location
Number of subjects: 0
Study 10396219 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D irradiation technique
Number of subjects: 9
Study 10396219 — intervention group
Group type: COMPARATOR
Intervention: 2D irradiation technique (simulated)
Number of subjects: 9
Study 7742084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 treatment
Number of subjects: 75
Study 7742084 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids and mineralocorticoids
Number of subjects: 75
Study 2043077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic rinse/storage (neomycin‐polymyxin B‐gramicidin)
Number of subjects: 76
Study 2043077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone‐iodine immersion
Number of subjects: 76
Study 2043077 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 76
Study 7028312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (Tagamet)
Number of subjects: 20
Study 7028312 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride (Phenergan)
Number of subjects: 20
Study 7028312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Promethazine combination
Number of subjects: 20
Study 30006513 — intervention group
Group type: EXPERIMENTAL
Intervention: 30g whey protein (120 kcal)
Number of subjects: 16
Study 30006513 — intervention group
Group type: EXPERIMENTAL
Intervention: 70g whey protein (280 kcal)
Number of subjects: 16
Study 30006513 — intervention group
Group type: COMPARATOR
Intervention: Flavoured-water control drink (2 kcal)
Number of subjects: 16
Study 30006513 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein ingestion
Number of subjects: 16
Study 26853238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-trampoline exercise (50 minutes, moderate-to-high intensity 70-85% HRmax)
Number of subjects: 24
Study 26853238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 24
Study 24126895 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g·kg(‐1) body mass)
Number of subjects: 8
Study 24126895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride NaCl: 0.045 g·kg(‐1) body mass)
Number of subjects: 8
Study 22581634 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with double posteriorly based nasal and lacrimal flaps
Number of subjects: 74
Study 22581634 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic DCR
Number of subjects: 74
Study 22581634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 74
Study 20543025 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation intervention (500 min of linguistically and cognitively complex talk over 10 weeks, 25 min twice weekly)
Number of subjects: 73
Study 20543025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 73
Study 18789068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 120
Study 15954115 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (300 mJ/pulse, 10 Hz, defocused mode)
Number of subjects: 10
Study 15954115 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (4-6 W, 20-50 Hz, focused mode)
Number of subjects: 10
Study 12028854 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or 8 mg/day of buprenorphine
Number of subjects: 23
Study 10051269 — intervention group
Group type: EXPERIMENTAL
Intervention: AERO + ST
Number of subjects: 45
Study 10051269 — intervention group
Group type: COMPARATOR
Intervention: AERO
Number of subjects: 45
Study 7670648 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor (n = 135)
Number of subjects: 266
Study 7670648 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-antagonist (n = 131)
Number of subjects: 266
Study 7670648 — intervention group
Group type: COMPARATOR
Intervention: ACE-inhibitor and Calcium-antagonist
Number of subjects: 266
Study 2166885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) 4 mg four times daily
Number of subjects: 202
Study 2166885 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BD) 0.1 mg four times daily
Number of subjects: 202
Study 2166885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 6269038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 100
Study 6269038 — intervention group
Group type: COMPARATOR
Intervention: Barrier methods (foam, condom, and/or diaphragm)
Number of subjects: 100
Study 6269038 — intervention group
Group type: COMPARATOR
Intervention: Barrier methods
Number of subjects: 100
Study 30259346 — intervention group
Group type: EXPERIMENTAL
Intervention: Active visualisation intervention
Number of subjects: 111
Study 30259346 — intervention group
Group type: COMPARATOR
Intervention: Standard care (including adherence counselling)
Number of subjects: 111
Study 26780267 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT)
Number of subjects: 99
Study 26780267 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 99
Study 24799354 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailings
Number of subjects: 237
Study 24799354 — intervention group
Group type: COMPARATOR
Intervention: Newspaper advertisements
Number of subjects: 237
Study 24799354 — intervention group
Group type: COMPARATOR
Intervention: Community outreach
Number of subjects: 237
Study 24291230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella denervation (n = 63)
Number of subjects: 126
Study 24291230 — intervention group
Group type: COMPARATOR
Intervention: No patella denervation (n = 63)
Number of subjects: 126
Study 22155939 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 232
Study 22155939 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo TSST)
Number of subjects: 232
Study 20850800 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal brain MRI studies
Number of subjects: 0
Study 17400089 — intervention group
Group type: EXPERIMENTAL
Intervention: PS implants designed for increased flexion
Number of subjects: 20
Study 17400089 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior-stabilized (PS) implants
Number of subjects: 20
Study 16350714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alpha‐OHD3 (0.5 microg/d) and calcium carbonate (1 g daily)
Number of subjects: 51
Study 16350714 — intervention group
Group type: COMPARATOR
Intervention: Complete androgenic blockade (orchidectomy + flutamide 750 mg daily)
Number of subjects: 51
Study 11874926 — intervention group
Group type: COMPARATOR
Intervention: Diet Only (DO)
Number of subjects: 38
Study 11874926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Aerobic Exercise (DA)
Number of subjects: 38
Study 11874926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Resistance Exercise (DR)
Number of subjects: 38
Study 10440140 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 3117
Study 10440140 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 3117
Study 10440140 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator
Number of subjects: 3117
Study 1729065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 46
Study 1729065 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (2.25 mg/kg bolus + 20 micrograms/kg/min)
Number of subjects: 46
Study 1729065 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 46
Study 1729065 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 46
Study 6741156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline
Number of subjects: 0
Study 6741156 — intervention group
Group type: COMPARATOR
Intervention: Traditional prolonged-action theophylline-ethylenediamine preparation
Number of subjects: 0
Study 31248307 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 10 weeks
Number of subjects: 52
Study 31464855 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck shortening (measured as a categorical variable: no shortening, mild shortening (≤5 mm), moderate shortening (6‐10 mm), severe shortening (>10 mm))
Number of subjects: 350
Study 29224639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based renal denervation (Paradise)
Number of subjects: 0
Study 29224639 — intervention group
Group type: COMPARATOR
Intervention: Renal angiogram (sham)
Number of subjects: 0
Study 29224639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care medication
Number of subjects: 0
Study 26742777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg/day in combination with allopurinol
Number of subjects: 227
Study 26742777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg/day in combination with allopurinol
Number of subjects: 227
Study 26742777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 600 mg/day in combination with allopurinol
Number of subjects: 227
Study 26742777 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with allopurinol
Number of subjects: 227
Study 26265792 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified high-intensity interval training (HIIT)
Number of subjects: 23
Study 26265792 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 23
Study 26265792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 23720096 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education intervention
Number of subjects: 34
Study 23720096 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study 20624069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine + lamivudine + efavirenz (group A)
Number of subjects: 65
Study 20624069 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine + lamivudine + ritonavir-boosted indinavir (group B)
Number of subjects: 65
Study 17906313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored injury prevention information (T‐IPI)
Number of subjects: 0
Study 17906313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored injury prevention information (T‐IPI) supplemented with a tailored summary for providers
Number of subjects: 0
Study 17906313 — intervention group
Group type: COMPARATOR
Intervention: Generic injury prevention information
Number of subjects: 0
Study 16467063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardica PAS-port aortic connector
Number of subjects: 24
Study 16467063 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 24
Study 14967866 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHOexo (1 g glucose x kg x h(‐1))
Number of subjects: 14
Study 14967866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially sweetened)
Number of subjects: 14
Study 10758775 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Azectol)
Number of subjects: 17
Study 10758775 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 17
Study 9209643 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-range nested polymerase chain reaction (PCR) using 0.5 microgram of DNA (60,000-80,000 cells)
Number of subjects: 144
Study 9209643 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-range PCR
Number of subjects: 144
Study 8209462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmilen, ethacirine, ethmorin with allapinin
Number of subjects: 0
Study 3040918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (VDS)
Number of subjects: 279
Study 3040918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU), Cyclophosphamide (CTX), Methotrexate (MTX)
Number of subjects: 279
Study 3040918 — intervention group
Group type: EXPERIMENTAL
Intervention: All four drugs (VDS, CCNU, CTX, MTX)
Number of subjects: 279
Study 3040918 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dose‐limiting toxicity
Number of subjects: 279
Study 30024485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (PER)
Number of subjects: 11
Study 30024485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (HY)
Number of subjects: 11
Study 30024485 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (Control)
Number of subjects: 11
Study 28771657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 6119
Study 26928185 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography-guided femoral nerve block (FNB)
Number of subjects: 90
Study 26928185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative periarticular injection (PAI)
Number of subjects: 90
Study 26928185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FNB and PAI
Number of subjects: 90
Study 26928185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 25536736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm titanium clips
Number of subjects: 100
Study 25536736 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Trisector (Gyrus, USA) (PTG)
Number of subjects: 100
Study 25536736 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical silk
Number of subjects: 100
Study 22494081 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group (PG) feedback
Number of subjects: 73
Study 22494081 — intervention group
Group type: COMPARATOR
Intervention: Practice visit (PV) feedback
Number of subjects: 73
Study 20150283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT)
Number of subjects: 1211
Study 20150283 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CON)
Number of subjects: 1211
Study 20150283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT) in adolescents
Number of subjects: 1211
Study 20150283 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CON) in adolescents
Number of subjects: 1211
Study 17901414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 201
Study 17901414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 16030027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 176
Study 16030027 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 176
Study 16030027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 176
Study 12598237 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat
Number of subjects: 52